PRTO

  0%
Previous Close
Open
Price To Book
Market Cap 0
Shares 0
Volume 0
Short Ratio
Av. Daily Volume 0
Stock charts supplied by TradingView

NewsSee all news

  1. ArTara Therapeutics Completes Merger Transaction with Proteon Therapeutics

    Shares of ArTara to commence trading on Nasdaq under new ticker symbol "TARA" effective January 10, 2020 Company completes previously announced equity financing of $42.5 million concurrently with the closing of the

  2. Proteon Therapeutics Announces Third Quarter 2019 Financial Results

    WALTHAM, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. ("Proteon" or the "Company") (NASDAQ:PRTO), a company that has historically focused on the development of novel, first-in-class

  3. Proteon Therapeutics and ArTara Therapeutics Agree to Combine

    Transaction to Create NASDAQ-Listed Rare and Specialty Disease Therapeutic Company Focused on Immunology and Metabolic Disorders $42.5M Concurrent Financing to be Led by a Syndicate of Healthcare Dedicated Investors

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data released December 13, 2016 - primary endpoint not met.
Vonapanitase (PRT-201) PATENCY-1
Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF)
Phase 3 data released Match 28, 2019 did not meet primary endpoint.
Vonapanitase (PRT-201) PATENCY-2
Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF)
Phase 1 enrolment to be completed by the end of 2019.
Vonapanitase (PRT-201)
Peripheral artery disease (PAD)

Latest News

  1. ArTara Therapeutics Completes Merger Transaction with Proteon Therapeutics

    Shares of ArTara to commence trading on Nasdaq under new ticker symbol "TARA" effective January 10, 2020 Company completes previously announced equity financing of $42.5 million concurrently with the closing of the

  2. Proteon Therapeutics Announces Third Quarter 2019 Financial Results

    WALTHAM, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. ("Proteon" or the "Company") (NASDAQ:PRTO), a company that has historically focused on the development of novel, first-in-class

  3. Proteon Therapeutics and ArTara Therapeutics Agree to Combine

    Transaction to Create NASDAQ-Listed Rare and Specialty Disease Therapeutic Company Focused on Immunology and Metabolic Disorders $42.5M Concurrent Financing to be Led by a Syndicate of Healthcare Dedicated Investors